ARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

This Study is
No Longer Enrolling

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 17-1992

More information available at ClinicalTrials.gov: NCT02567435

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers